Evidence map›Paper›PMID 37043709›Full record

ArticleJCO global oncology2023

Virologic Nonsuppression Among Patients With HIV Newly Diagnosed With Cancer at Uganda Cancer Institute: A Cross-Sectional Study.

Geraldine Kauma, Henry Ddungu, Isaac Ssewanyana, Sharon Nyesiga, Naghib Bogere, Teddy Namulema-Diiro, Pauline Byakika-Kibwika, Elizabeth Namukwaya, Harriet Mayanja Kizza

Abstract read
In one paragraph

Article in JCO global oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Geraldine KaumaUganda Cancer Institute, Kampala, Uganda.ORCID 0000-0003-3443-3165
Henry DdunguUganda Cancer Institute, Kampala, Uganda.ORCID 0000-0001-9227-4030
Isaac SsewanyanaUganda Central Public Health Laboratory, Kampala, Uganda.
Sharon NyesigaUganda Heart Institute, Kampala, Uganda.ORCID 0000-0003-0009-5030
Naghib BogereUganda Cancer Institute, Kampala, Uganda.ORCID 0000-0001-6473-8272
Teddy Namulema-DiiroVictorville Clinic Gayaza, Wakiso, Uganda.
Pauline Byakika-KibwikaDepartment of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0003-0757-1968
Elizabeth NamukwayaDepartment of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0001-5241-2742
Harriet Mayanja KizzaDepartment of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAIDS-related mortality declined markedly since the introduction of antiretroviral therapy (ART); however, cancer mortality in Africa was higher than its incidence in 2020. People living with HIV (PLWHIV) are at an increased risk of malignancy and death from malignancy compared with the general population. In Uganda, AIDS-defining malignancies (ADMs), including cervical cancer, Kaposi sarcoma, and non-Hodgkin lymphoma, are among the commonest malignancies. Virologic nonsuppression has been identified as an important predictor of mortality among PLWHIV diagnosed with cancer. This study aimed to determine the prevalence and to identify factors associated with virologic nonsuppression among PLWHIV newly diagnosed with cancer.

methodsThis was a cross-sectional study that was carried out between December 2018 and April 2019 at the Uganda Cancer Institute. PLWHIV who had been on ART for at least 6 months and were newly diagnosed with cancer were enrolled.

resultsA total of 167 participants were enrolled. Cervical cancer was the commonest ADM (n = 45; 50.6%) of all ADMs, while esophageal and breast cancers were the commonest non-ADMs, accounting for 17.5% (n = 14) each of all non-ADMs. The prevalence of virologic nonsuppression was 15%. Having Kaposi sarcoma (odds ratio [OR], 8.15;

conclusionThe prevalence of virologic nonsuppression is high among patients with HIV newly diagnosed with cancer. These findings emphasize the need for strengthening of adherence strategies, optimizing ART regimens, and prioritization of viral load testing among PLWHIV with newly diagnosed malignancy.

Indexed as

Acquired Immunodeficiency SyndromeAnti-HIV AgentsHIV InfectionsSarcoma, KaposiUterine Cervical NeoplasmsCross-Sectional StudiesFemaleHumansUgandaAnti-HIV Agents

Identifiers

PMID37043709
PMCPMC10281357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.